Biotheranostics Announces Chief Commercial Officer
April 01, 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, April 01, 2020 (GLOBE NEWSWIRE) -- On April 1, 2020, company veteran and Vice President of Sales, Matt Sargent, was promoted to the position of Chief Commercial Officer. In this...
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
February 24, 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology. The...
Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index® Test
December 11, 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces the launch of its Not Another Minute campaign, revealing how Breast Cancer Index (BCI) is changing the game for...
Biotheranostics to Present New Data Expanding the Clinical Utility of Breast Cancer Index® at the 42nd Annual San Antonio Breast Cancer Symposium
December 10, 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc. announced today that several abstracts featuring updates on ongoing research and new data examining the Breast Cancer Index®...
Breast Cancer Index® publishes new pivotal data strengthening clinical evidence as a predictive factor of benefit from endocrine therapy
September 06, 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Sept. 06, 2019 (GLOBE NEWSWIRE) -- SAN DIEGO, Calif., September 5, 2019 – Biotheranostics, Inc. today announced new pivotal data on the Breast Cancer Index® (BCI) published in the...
Biotheranostics appoints F. Anthony Greco, M.D. as Medical Advisor for its CancerTYPE ID® molecular assay
July 01, 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, July 01, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces F. Anthony Greco, MD as Medical Advisor for its CancerTYPE ID® test. CancerTYPE ID helps with identification of...
Breast Cancer Index® and new data on its power to predict extended endocrine therapy benefit presented at ASCO 2019
June 03, 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, June 03, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index® (BCI) being presented at the ASCO conference June 3, 2019 that further...
Biotheranostics announces Lee Newcomer, M.D. to join its Board of Directors
May 21, 2019 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, May 21, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., today announced that Lee Newcomer, M.D., has been elected to its Board of Directors. Dr. Newcomer brings more than 30 years of...
Breast Cancer Index® Now Covered by Medicare for a Broader Group of Post-Menopausal Patients Considering Extended Endocrine Therapy
April 16, 2019 09:00 ET
|
Biotheranostics, Inc.
San Diego, California, April 16, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc. announces expanded Medicare coverage for its Breast Cancer Index® test under a new Local Coverage Determination [(LCD)...
Breast Cancer Index® Receives Expanded Medicare Coverage Under a New Local Coverage Determination
March 05, 2019 09:00 ET
|
Biotheranostics, Inc.
San Diego, CA, March 05, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces its Breast Cancer Index (BCI) test has been issued a new Medicare Local Coverage Determination [(LCD) L37822] by...